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ABSTRACT
An open, prospective, randomised study was conducted to compare the safety and efficacy of
valacyclovir vs. oral ganciclovir for cytomegalovirus (CMV) prophylaxis in renal transplant recipients.
Eighty-three renal transplant recipients were assigned randomly to receive valacyclovir (n = 43) or oral
ganciclovir (n = 40) for the first 3 months after transplantation. Both groups were similar in terms of
demographics, primary renal disease, graft source, HLA matching, immunosuppressive therapy and
donor–recipient CMV antibody status. CMV infection was diagnosed by detection of virus DNA in
plasma with the Amplicor CMV Test. CMV disease was observed in only one patient belonging to the
ganciclovir group, who developed enterocolitis 6 months post-transplantation. No difference was
observed between the two treatment groups with respect to detection of CMV DNA, virus infections
other than CMV, acute rejection episodes, and serum creatinine levels at 3 and 6 months following
transplantation. An increased number of bacterial infections was noted in the ganciclovir group
(p 0.003). No adverse reactions with either treatment were reported. The estimated cost of valacyclovir
treatment was 20% higher than that of ganciclovir treatment. Overall, both valacyclovir and oral
ganciclovir were found to be effective and safe for CMV prophylaxis in renal transplant recipients.
Decisions regarding prophylactic regimens should include additional criteria, such as cost or possible
development of resistance.
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INTRODUCTION
Cytomegalovirus (CMV) is the most common
cause of infectious complications following solid-
organ transplantation (SOT), and contributes sig-
nificantly to morbidity, hospital readmission and
mortality in advanced cases [1]. Furthermore,
CMV infection results, independently, in
enhanced immunosuppression and a higher inci-
dence of other opportunistic superinfections [2],
and has been recognised as a risk-factor for acute
and chronic graft rejection [3]. All these direct and
indirect effects of CMV infection contribute,
ultimately, to the overall costs of transplantation
programmes [4].
CMV infection and disease occur in 10–60% of
all renal transplant recipients, most frequently
during the period of maximal immunosuppres-
sion between 6 weeks and 6 months post-
transplantation [5]. Disease manifestations range
from a mild viral syndrome to life-threatening
multi-organ involvement (pneumonitis, hepatitis,
retinitis and gastrointestinal disease), with the
risk being highest in seronegative patients (R–)
who receive a transplant from a CMV-seroposit-
ive donor (D+) [6]. Other risk-factors include the
net state of immunosuppression, determined by
the precise immunosuppression protocol and
various host factors.
The availability of effective therapy has
reduced the mortality rate from invasive CMV
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disease, but the significant morbidity and eco-
nomic burden associated with this virus still
remain a problem in this specific patient popu-
lation [7]. Therefore, prophylaxis with antiviral
agents has, in recent years, seemed to be the
most effective approach [1]. Various agents have
proved successful in preventing CMV infection
and disease in transplant patients, with intra-
venous ganciclovir being the initial drug of
choice for both prevention and treatment [8].
The associated risk of neutropenia, and the
increased need for patient hospitalisation follow-
ing its use, have led subsequently to the devel-
opment of oral formulations. Oral ganciclovir
has been shown to be effective in preventing
CMV disease, but its low bioavailability limits
the degree of viral suppression and may predis-
pose to the emergence of resistance [8,9]. Valg-
anciclovir, the valine ester of ganciclovir, was
developed in an oral formulation to overcome
the low bioavailability of ganciclovir. A single,
once-daily, oral dose of 900 mg provides plasma
ganciclovir levels comparable to a 5 mg ⁄ kg dose
of intravenous ganciclovir [10,11]. Valganciclovir
is approved currently in Europe and the USA for
the treatment of active CMV retinitis in AIDS
patients, and for the prevention of CMV disease
in kidney, heart and kidney–pancreas transplant
patients at high risk (D+R–) of infection.
Although high-dose oral acyclovir is well-
tolerated and reduces the risk of CMV disease
in renal and other solid-organ transplants, its
prophylactic use with such patients has not
gained wide acceptance [12]. In addition, one
study [13] indicated that oral acyclovir was less
effective than oral ganciclovir for CMV pro-
phylaxis in high-risk renal transplant recipients.
Valacyclovir, a pro-drug of acyclovir, which has
a higher level of bioavailability, has proved to
be a safe and effective way to prevent CMV
disease after renal transplantation, and also
decreases the risk of acute graft rejection
[14,15]. In recent years, the antiviral agents
used most commonly for CMV prophylaxis
have been oral ganciclovir and valacyclovir.
However, comparative data regarding the safety,
efficacy and cost of these two drugs are very
limited. The present report describes an open,
prospective, randomised study designed to com-
pare the safety, efficacy and cost of valacyclovir
vs. oral ganciclovir for CMV prophylaxis with
renal transplant recipients.
MATERIALS AND METHODS
Study design
The study was conducted between April 1999 and September
2000 at the Renal Transplant Centre of Laiko General
Hospital (Athens, Greece). This is a referral centre that
performed almost 50% of the entire country’s renal trans-
plantations between 1990 and 1999 [16]. According to the
inclusion criteria for the present study, eligible patients were
individuals aged ‡ 14 years who received a renal transplant
from a living or deceased donor, regardless of the CMV
serological status of the recipient and donor. Patients were
excluded if they had active herpes virus infection or if they
had received other antiviral agents in the 2 weeks before
transplantation. Participants were assigned randomly in a 1:1
ratio to receive either valacyclovir (Valtrex; Glaxo-Wellcome,
Uxbridge, UK) 2 g every 6 h, or oral ganciclovir (Cymevene;
Hoffman-La Roche, Welwyn Garden City, UK), 1 g every
8 h. Doses were adjusted on the basis of renal function
[8,17].
Prophylaxis was started within 72 h of transplantation and
was continued for 3 months. Written informed consent was
obtained from each patient or his legal guardian. The CMV
serological status of donors and recipients was determined by
detection of IgG-specific antibodies by indirect immunofluo-
rescence (IFA CMV test; Gull Laboratories, Salt Lake City, UT,
USA). The efficacy of prophylaxis, as well as patient and graft
survival, were assessed for a period of 6 months post-trans-
plantation. Anti-CMV therapy, with concurrent adjustment of
immunosuppression if needed, could be initiated at any time
during the period of prophylaxis when CMV disease was
diagnosed (as defined below). Safety was monitored by clinical
evaluation, haematological and biochemical parameters, and
urinalysis, and adverse events were recorded. Viraemia was
confirmed by qualitative detection of CMV DNA in plasma by
the Amplicor CMV Test (Roche Molecular Systems, Branch-
burg, NJ, USA) before transplantation, once-weekly during
hospitalisation, bi-weekly until month 3, and then monthly
until month 6.
Primary endpoints were the occurrence of CMV infection
and ⁄ or disease during the first 6 months following trans-
plantation, and drug-related adverse events during prophy-
laxis. Secondary endpoints were the frequency of acute graft
rejection, the occurrence of bacterial and virus infections
other than CMV, renal function (as monitored by serum
creatinine levels), and the relative costs of the two prophy-
lactic regimens.
Definitions
CMV disease was defined as CMV viraemia with fever of
‡ 38C for at least 3 consecutive days and one of the following:
leukopenia, thrombocytopenia, pneumonitis, gastrointestinal
disease, hepatitis, retinitis, nephritis or other clinically signi-
ficant constitutional symptoms. Alternatively, CMV disease
was defined as any febrile illness accompanied by CMV
viraemia that was responsive to ganciclovir treatment only.
CMV infection was defined as CMV viraemia in the absence of
any clinical or laboratory parameters that could be attributed
to CMV. Other infections comprised (1) all infectious episodes
attributed to herpes viruses other than CMV, and (2) infec-
tions, other than those caused by herpes viruses, that required
hospitalisation.
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Pharmaco-economic analysis
The total cost of the drugs administered and the hospital-
related expenses were estimated for each treatment group.
Valacyclovir is currently marketed to hospitals in Greece in
packs containing 42 · 500 mg tablets at a cost of €66.20
per pack. Ganciclovir is marketed in packs containing
90 · 500 mg capsules at a cost of €488.70 per pack. Ganciclo-
vir and valacyclovir dosages were calculated for creatinine
clearance of 50–75 mL ⁄min, which was the usual renal
function after stabilisation of the patient had been achieved,
within 1 and 3 weeks after transplantation. The mean cost of
hospitalisation in the National Health Service in Greece is
€88.00 per day.
Statistical analysis
Data were processed and analysed using SPPS v. 10.0 for
Windows (SPSS Inc., Chicago, IL, USA). All values were
expressed as the mean ± SD. Qualitative and quantitative
variables were analysed by chi-square test or Fisher’s exact test
and t-test, respectively, with p < 0.05 considered to be
significant.
RESULTS
Patient characteristics
During the study period, 100 patients underwent
renal transplantation, with 59 receiving a kidney
from a living donor and 41 from a deceased
donor. Eighty-three renal transplant recipients
fulfilled the inclusion criteria and completed the
trial; 43 (group I) received valacyclovir, and 40
(group II) received ganciclovir, for a total of
3 months post-transplantation. Doses of either
agent were adjusted according to renal function
(Table 1).
Table 2 summarises the patient characteristics
of the two treatment groups. There were no
significant differences between the two treatment
groups with respect to gender, age, graft source,
HLA matching, cause of end-stage renal disease
and donor–recipient CMV status. Most recipients
(c. 75%) and donors (c. 70%) were seropositive for
CMV. In both treatment groups, six of ten
seronegative recipients (14% of group I and
15% of group II; p, not significant) received grafts
from seropositive donors.
Most kidney transplant recipients received
induction therapy with monoclonal antibody
against interleukin-2 receptors, mainly
basiliximab in combination with mycophenolate
mofetil, calcineurin inhibitor, mainly neoral, and
methylprednisolone. Few patients received anti-
lymphocyte antibody, and only a small group
received sirolimus. No differences were noted
between treatment groups with respect to immu-
nosuppression.
Mean daily doses of valacyclovir and ganci-
clovir administered were 5.4 g and 1.3 g,
respectively. Patient compliance was 100% for
both treatment groups, and both antiviral drugs
were well-tolerated. No adverse events that
could be attributed to either drug were recorded
during the 3-month period of prophylactic treat-
ment.
Table 1. Dosing adjustments based on creatinine clear-
ance
Creatinine
clearance
(mL ⁄min)a
Valacyclovir
(g ⁄day, 500-mg tablets)
Ganciclovir
(g ⁄day, 500-mg capsules)
> 75 8 (2 tablets four-times daily) 3 (1 capsule three-
times-daily)
75–50 6 (1.5 tablets four-times-daily) 1.5 (0.5 capsule three-
times-daily)
50–25 4.5 (1.5 tablets three-times-daily) 1 (0.5 capsule once ⁄day)
25–10 3 (1.5 tablets twice-daily) 0.5 (0.5 capsule once ⁄day)
< 10 or patient
on dialysis
1.5 (1.5 tablets daily) 0.5 (3 times ⁄week)
aCreatinine clearance calculated using the Cockcroft–Gault formula.
Table 2. Patient characteristics at entry to the study
Characteristic
Group Ia
(n = 43)
Group IIb
(n = 40) p value
Gender
Male 34 (79%) 29 (72.5%) NS
Female 9 (21%) 11 (27.5%) NS
Mean age, years ± SD 40.7 ± 12 43.1 ± 15 NS
Graft
Live, related 28 (65%) 23 (57.5%) NS
Cadaveric 15 (35%) 17 (42.5%) NS
Tissue matching, mean no. of
common antigens ± SD
3.9 ± 1.6 4.1 ± 2.2 NS
Cause of renal failure
Diabetes 4 (9%) 4 (10%) NS
Hypertensive
nephrosclerosis
3 (7%) 4 (10%) NS
Glomerulonephritis 14 (33%) 12 (30%) NS
Interstitial nephritis 3 (7%) 2 (6%) NS
Multicystic disease 4 (9%) 4 (10%) NS
Other 15 (35%) 14 (35%) NS
CMV serological statusc
D+R– 6 (14%) 6 (15%) NS
D+R+ 24 (56%) 23 (57.5%) NS
D–R+ 9 (21%) 7 (17.5%) NS
D–R– 4 (9%) 4 (10%) NS
CMV DNA at entry 0 0 NS
Immunosuppression
Anti-lymphocyte
antibody
4 (9%) 2 (5%) NS
BAS ⁄MMF ⁄N ⁄MP 19 (44%) 23 (57.5%) NS
DAC ⁄MMF ⁄TAC ⁄MP 4 (9%) 2 (5%) NS
SIR ⁄N ⁄MP 9 (21%) 2 (5%) NSd
MMF ⁄TAC ⁄MP 11 (26%) 13 (32.5%) NS
aGroup I, valacyclovir, 2 g every 6 h.
bGroup II, ganciclovir, 1 g every 8 h.
cD, donor; R, recipient.
dp 0.07.
BAS, basiliximab; MMF, mycophenolate mofetil; N, neoral (cyclosporin A); MP,
methylprednisolone; DAC, daclirumab; TAC, tacrolimus; SIR, sirolimus; CMV,
cytomegalovirus; NS, not significant (p ‡ 0.05).
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CMV disease and infection
Only one male patient, belonging to the ganciclo-
vir group, developed CMV disease. This was a
seronegative recipient who received an allograft
from a seropositive donor, and who developed
CMV colitis 6 months after renal transplantation.
The patient responded well to intravenous treat-
ment with ganciclovir for 2 weeks, followed by
oral administration for 1 week, with no further
relapses. No patient from the valacyclovir group
developed CMV disease.
Overall, CMV infection developed in 19% and
17.5% of group I and group II patients, respect-
ively (p, not significant). The differences in
CMV infection rates between the two groups
were not significant when calculated separately
for the periods 0–3 months and 3–6 months
post-transplantation. Furthermore, no statistical
difference was noted in CMV infection rates
between the two prophylactic groups when
calculated with respect to recipient CMV status
(Table 3). Two (6%) of 33 seropositive recipients
in the valacyclovir group experienced active
CMV infection, compared with four (13%) of 30
seropositive patients in the ganciclovir group.
All seronegative patients who developed active
CMV infection (six (60%) of ten in group I;
three (33%) of ten in group II) received grafts
from seropositive donors. The incidence of
active CMV infection was significantly higher
among the seronegative recipients in both
groups than in those who were seropositive
(p < 0.01).
Other herpesvirus diseases, including herpes
simplex, varicella-zoster and Epstein–Barr virus
infection, developed in one (2%) and two (5%)
patients in groups I and II, respectively (p, not
significant).
The risk of other, non-virus, infections was
significantly higher in the ganciclovir group
(90%) than in the valacyclovir group (53.5%;
p 0.003; Table 4). This difference was caused
mainly by the higher rates of urinary tract
infection observed in group II. Five of six episodes
of bacteraemia in group I and three of four
episodes of bacteraemia in group II were secon-
dary to urinary tract infections that were the
primary cause of bacterial infection. Two episodes
of Candida infection (vulvovaginitis and cystitis)
were recorded in the ganciclovir group. All cases
of infection were treated successfully and no
deaths or cases of graft loss or permanent deteri-
oration of renal function were observed. Acute
rejection episodes were similar for both groups
(11.6% in group I; 12.5% in group II) and were
treated successfully with intravenous pulses of
methylprednisolone. No patient had developed
graft dysfunction, proteinuria or chronic graft
nephropathy at 6 months. Finally, there were no
differences in renal function, expressed as serum
creatinine levels (mg ⁄dL), between the two treat-
ment groups at months 3 and 6 after transplan-
tation (month 3, 1.6 ± 0.7 vs. 1.6 ± 0.4, and month
6, 1.5 ± 0.4 vs. 1.6 ± 0.4, in groups I and II,
respectively; p, not significant).
Pharmaco-economic analysis
Use of medical inpatient and outpatient
resources, including days spent in hospital, and
costs for procedures and inpatient and outpatient
laboratory tests, were similar for the two treat-
ment groups. In addition, there was no difference
in the use of intravenous ganciclovir as a treat-
ment for CMV disease between the two groups.
Table 3. Cytomegalovirus (CMV) disease and infection in
relation to prophylactic treatment post-transplantation
Group I
n (%)
Group II
n (%) p value
CMV disease 0 1 (2.5) NS
CMV infection 8 (19) 7 (17.5) NS
0–3 months 6 (14) 3 (7.5) NS
3–6 months 2 (5) 4 (10) NS
CMV infection in
seropositive patients
2 (6) 4 (13) NS
0–3 months 1 (3) 2 (6.5) NS
3–6 months 1 (3) 2 (6.5) NS
CMV infection in
seronegative patients
6 (60) 3 (33) NS
0–3 months 5 (50) 1 (11) NS
3–6 months 1 (10) 2 (22) NS
NS, not significant.
Table 4. Infections other than cytomegalovirus
Infection
Group I
n (%)
Group II
n (%) p value
Herpesviruses 1 (2) 2 (5) NS
EBV 0 1 (2.5) NS
HZV 1 (2) 0 NS
HSV 0 1 (2.5) NS
Non-viral infections 23 (54) 36 (90) 0.003
UTI 10 (23) 20 (53) < 0.02
Bacteraemia 6 (14) 4 (10) NS
Pneumonia 5 (12) 6 (15) NS
Wound infection 2 (5) 4 (10) NS
Candidiasis 0 2 (5) NS
EBV, Epstein–Barr virus; HZV, herpes-zoster virus; HSV, herpes simplex virus;
UTI, urinary tract infection; NS, not significant (p ‡ 0.05).
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Therefore, in order to evaluate the economics of
both prophylactic strategies, only the costs of the
two antiviral agents were compared. Drug dosage
was calculated for a creatinine clearance of
50–75 mL ⁄min, with normal renal function
achieved usually at 1–3 weeks post-transplanta-
tion, with the result that the real cost is slightly
lower than the estimated cost (the fact that renal
function was similar in both study groups means
that this should not have any effect on the
comparison). Thus, renal transplant patients with
a creatine clearance of 50–75 mL ⁄min received 6 g
(actual mean dose of 5.4 g) of valacyclovir daily
(i.e., 12 tablets), with an estimated cost over
3 months of €1721. Similarly, the total daily dose
was 1.5 g (actual mean dose of 1.3 g) of ganciclo-
vir (i.e., three capsules), with an estimated cost
over 3 months of €1466.
DISCUSSION
The findings of this study indicate that valacyclo-
vir and oral ganciclovir are both safe and effective
in preventing CMV disease or infection in renal
transplant recipients.
Since most (91%) of the study participants were
CMV-seropositive, or received a graft from a
CMV-seropositive donor, a high proportion of
individuals were at risk of developing CMV
disease. Based on previous studies including
similar patient populations, a significant inci-
dence of CMV infection and disease (10–60%) is
expected in renal transplant recipients during the
6 months following transplantation, usually rep-
resenting virus reactivation or new infection by a
different strain of CMV [5,18].
No difference was observed between the two
groups regarding demographics, CMV serological
status of donors and recipients, or type of immu-
nosuppression regimen, which, in the present
study, followed the latest protocols used in renal
transplantation. In contrast, previous studies did
not use monoclonal antibodies against interleu-
kin-2 receptors, or sirolimus or tacrolimus as
routine treatment [19,20]. In addition, the propor-
tion of the study population receiving induction
or anti-rejection therapy with anti-lymphocyte
antibody was low in comparison with other
studies [19,20].
Only one of the patients in the ganciclovir
group developed CMV disease (colitis) within
6 months of transplantation. Delayed appearance
of CMV disease has been described in patients
receiving valacyclovir prophylaxis [15], but the
incidence of CMV disease in those patients was
reported to be 3% within 3 months of transplan-
tation, and 16% at month 6.
Compliance with both treatments was 100%.
The absence of adverse events was probably the
result of careful dose adjustment according to
renal function. It is known that both antiviral
drugs are excreted through the kidneys, and an
appropriate dose adjustment is needed if renal
function is diminished. Similar studies have
reported satisfactory tolerance to both antiviral
agents, but specific information regarding the
frequency of appropriate dose adjustment is
lacking [15,19,20]. The present study calculated
the doses of both drugs with respect to the
estimated creatinine clearance, which is a more
reliable index of renal function than serum creat-
inine, each day during the first critical period
post-transplantation, twice-weekly for the follow-
ing month, and once-weekly up to month 3.
Regarding the indirect CMV consequences for
patient and graft, no differences were noted
between the two groups with respect to both
patient and graft survival (100%), the incidence of
acute rejection, serum creatinine levels at months
3 and 6, or the appearance of proteinuria. In a
previous study, valacyclovir was found to
decrease acute rejection episodes when compared
to a placebo [15]. However, according to the
results of a meta-analysis, other agents used for
CMV prophylaxis had no influence on the inci-
dence of acute rejection [21]. A retrospective
analysis of transplants reported by 435 centres
in 44 countries during 1985–2002 showed that
CMV prophylaxis with antiviral agents or anti-
CMV immunoglobulin was associated signifi-
cantly with improved graft and patient survival
at 3 years for seronegative recipients of a CMV-
seropositive organ transplant [22].
Considering virus infections other than CMV,
no difference was observed between the two
groups. The difference in bacterial infections in
favour of the valacyclovir patients was attributed
to the significantly higher number of urinary tract
infections within the ganciclovir group. A protect-
ive effect of valacyclovir prophylaxis for non-virus
infections has been found previously in a valacy-
clovir vs. placebo study in CMV-seronegative
renal transplant recipients [15], and was
considered to possibly reflect direct effects of
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valacyclovir, such as decreases in CMV-induced
immunosuppression and damage to integumen-
tary barriers. In addition, the decreased use of
anti-lymphocyte antibodies among valacyclovir
recipients (as a result of the decreased rate of acute
rejection) may also have decreased the rate of
other infections. There was no obvious explan-
ation in the present study for the lower rate of
bacterial infections in the patients receiving vala-
cyclovir, since all basic characteristics were similar
between the two study groups and no significant
reduction in neutrophil count was observed.
Nevertheless, this finding should be highlighted.
Previous studies have indicated a decreased
cost of transplantation with the use of CMV
prophylaxis, as a result of the lower incidence of
CMV infection [4,15,19,23,24]. However, compar-
ative data on prophylactic treatment with ganci-
clovir or valacyclovir are not available. The
present study calculated that prophylaxis with
valacyclovir increased costs by 21% when com-
pared to ganciclovir. This difference in cost could
be explained by the different reduction in dosages
between the two drugs. Treatment with ganciclo-
vir is more expensive than treatment with vala-
cyclovir in patients with normal renal function
(daily cost ⁄patient of €32.5 vs. €25.2). However,
all of the patients studied had a creatinine
clearance of 50–75 mL ⁄min, resulting in the need
for a 50% reduction in ganciclovir dosage vs. a
25% reduction for valacyclovir, according to
published pharmacokinetic data concerning the
two drugs. Other parameters should also be
considered in order to evaluate the significance
of this rather small difference in costs compared
to the total cost of renal transplantation. Since
tolerability, safety and effectiveness were similar
between the groups, the possibility of develop-
ment of resistance to these agents should also be
taken into account.
Despite the widespread use of prophylactic
regimens, CMV continues to pose a serious
problem in SOT [1] because of the use of novel,
more potent immunosuppressive agents that
decrease the incidence of graft rejection but, at
the same time, leave the patient highly susceptible
to various opportunistic infections, including
CMV [25,26]. According to a retrospective study,
renal transplant patients receiving triple immu-
nosuppressive therapy that includes cyclosporin,
steroids and mycophenolate mofetil, but no
anti-CMV prophylaxis, have a 67% incidence of
CMV disease, compared with an incidence of 30%
in patients receiving no mycophenolate mofetil
[27]. In addition, the onset of CMV mRNA
expression is significantly earlier in renal trans-
plant patients treated with mycophenolate mofetil
[28]. There is also recent evidence that mycophe-
nolate mofetil potentiates the anti-herpetic effects
of various compounds [29]. Thus, concomitant
administration of CMV prophylaxis with myco-
phenolate mofetil may result in a lower risk of
rejection and CMV disease than is seen with
either prophylaxis or mycophenolate mofetil
alone, compensating for the increased risk of
CMV disease associated with mycophenolate
mofetil treatment. Clearly, prophylactic protocols
need frequent re-evaluation in order to maintain
their effectiveness [30]. However, data regarding
the optimal choice for CMV prophylaxis are
scarce. In a recent study from the USA, oral
ganciclovir was compared with valacyclovir as
prophylaxis in 150 high-risk kidney transplant
patients [20]; the two drugs exhibited similar
efficacy in reducing both CMV infection and
disease, although the study was retrospective,
confirmation criteria for CMV disease were based
on diverse laboratory tests, and 50% of the
patients were treated with anti-lymphocyte glob-
ulin. In another study of 38 renal transplant
recipients in the Czech Republic [19], no differ-
ence was found between the small groups receiv-
ing ganciclovir or valacyclovir with respect to
CMV disease or infection, while a significantly
higher incidence of these events was reported in
the placebo group. The findings of the present
study are in agreement with these results.
Treating immunosuppressed patients for long
periods of time with antiviral agents exhibiting
poor bioavailability may facilitate the emergence
of resistant strains of virus [9,31]. In clinical
practice, the incidence of CMV infection with
resistant strains in SOT is unknown, but is thought
to be low [32]. Nevertheless, reports have started
to indicate that ganciclovir resistance may become
an important problem for the transplant popula-
tion, especially with the increasing use of this
agent for prolonged prophylactic treatment
[33–35]. Therefore, CMV infection or disease may
be caused to some extent by ganciclovir-resistant
CMV strains. To date, only one multicentre retro-
spective study has reported CMV resistance to
ganciclovir, in one of 23 renal transplant patients
who had received valacyclovir prophylaxis [36],
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with no reports of resistance to foscarnet [37].
Consequently, valacyclovir, as a ‘ganciclovir-
sparing’ regimen, enables ganciclovir to be
reserved for the treatment of established CMV
disease, and offers the advantage of presenting
less opportunity for drug resistance to develop.
There is increasing evidence, based on clinical
data, that valganciclovir is safe and effective in
preventing CMV disease in high-risk SOT pa-
tients, and that it is associated with a negligible
risk of resistance [38–41]. However, only two
prospective studies comparing ganciclovir with
valganciclovir in seronegative organ recipients
have been published, both of which demonstrated
similar results with the two drugs [41,42]. In the
absence of a comparative study between valg-
anciclovir and valacyclovir, it is not yet known
which prophylactic regimen is preferable for the
SOT population. Although the power of the
present study might not have been adequate to
detect differences between the two prophylactic
regimens, the present findings indicate that both
valacyclovir and oral ganciclovir are equally
effective and safe in preventing CMV disease in
renal transplant recipients. The decision as to
which regimen should be provided for prophy-
laxis to renal transplant patients is complex and
should be made after considering efficacy, toxic-
ity, cost and the possibility of emergence of
resistant strains. Further investigations are still
needed to define the optimal prophylactic regi-
men for this patient population.
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